# A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

> **NCT05791695** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 155413 (actual)

## Conditions studied

- Intraocular Inflammation
- Suspected Endophthalmitis

## Interventions

- **OTHER:** Non Applicable

## Key facts

- **NCT ID:** NCT05791695
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-16
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-09-15
- **Target enrollment:** 155413 (ACTUAL)
- **Last updated:** 2023-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05791695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05791695, "A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05791695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*